Serina Therapeutics And Enable Injection Announced A Partnership To Develop And Commercialize SER-252 (POZ-apomorphine) In Combination With Enfuse For The Treatment Of Parkinson's Disease
Portfolio Pulse from Benzinga Newsdesk
Serina Therapeutics and Enable Injection have announced a partnership to develop and commercialize SER-252 (POZ-apomorphine) in combination with Enfuse for the treatment of Parkinson's Disease.
May 15, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Serina Therapeutics has partnered with Enable Injection to develop and commercialize SER-252 (POZ-apomorphine) in combination with Enfuse for Parkinson's Disease treatment. This partnership could enhance Serina's product portfolio and market reach.
The partnership with Enable Injection to develop and commercialize a new treatment for Parkinson's Disease could significantly enhance Serina Therapeutics' product offerings and market presence, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100